AOI Biosciences Raises Approximately ¥500 Million Through Capital Increase and Share Transfer

AOI Biosciences, which specializes in antibody testing and drug discovery research in the fields of infertility and recurrent pregnancy loss, announced on the 14th that it has raised approximately ¥500 million through a third-party allotment and share transfer (secondary transaction). Read more. The investors include Japan Venture Capital, SBI Shinsei Corporate Investment, i-nest capital, GoAhead Ventures, Suho Investment Works, SBI Investment (SUMISEI-SBI Investment Business Limited Partnership

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.